MX2023001501A - Vacuna tau para tratamiento de enfermedad de alzheimer. - Google Patents
Vacuna tau para tratamiento de enfermedad de alzheimer.Info
- Publication number
- MX2023001501A MX2023001501A MX2023001501A MX2023001501A MX2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A
- Authority
- MX
- Mexico
- Prior art keywords
- tau
- disease
- alzheimer
- compositions
- peptides
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 abstract 2
- 230000002776 aggregation Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000035508 accumulation Effects 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062971P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/033189 WO2022031342A1 (en) | 2020-08-07 | 2021-05-19 | Tau vaccine for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001501A true MX2023001501A (es) | 2023-03-08 |
Family
ID=80118379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001501A MX2023001501A (es) | 2020-08-07 | 2021-05-19 | Vacuna tau para tratamiento de enfermedad de alzheimer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230302127A1 (https=) |
| EP (1) | EP4192583A4 (https=) |
| JP (1) | JP2023536746A (https=) |
| KR (1) | KR20230080398A (https=) |
| CN (1) | CN117751132A (https=) |
| AR (1) | AR122129A1 (https=) |
| AU (1) | AU2021321206A1 (https=) |
| CA (1) | CA3188458A1 (https=) |
| IL (1) | IL300346A (https=) |
| MX (1) | MX2023001501A (https=) |
| TW (1) | TW202221022A (https=) |
| WO (1) | WO2022031342A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN115894659B (zh) * | 2022-10-19 | 2023-11-10 | 上海优宁维生物科技股份有限公司 | 微管相关蛋白Tau抗原及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106390107B (zh) * | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| JP2013500326A (ja) * | 2009-07-30 | 2013-01-07 | ファイザー バクシーンズ エルエルシー | 抗原性タウペプチドおよびその使用 |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| JP6654899B2 (ja) * | 2013-12-26 | 2020-02-26 | 東亞合成株式会社 | カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド |
| WO2015165961A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| US20180050097A1 (en) * | 2015-03-25 | 2018-02-22 | Stc. Unm | Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse |
| KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| KR102784294B1 (ko) * | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| SG11202001826YA (en) * | 2017-10-16 | 2020-03-30 | Adjuvance Technologies Inc | Triterpene saponin analogues |
| EP3894438A1 (en) * | 2018-12-13 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
| JP7630834B2 (ja) * | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
-
2021
- 2021-05-19 MX MX2023001501A patent/MX2023001501A/es unknown
- 2021-05-19 US US18/020,037 patent/US20230302127A1/en active Pending
- 2021-05-19 AU AU2021321206A patent/AU2021321206A1/en active Pending
- 2021-05-19 IL IL300346A patent/IL300346A/en unknown
- 2021-05-19 CA CA3188458A patent/CA3188458A1/en active Pending
- 2021-05-19 WO PCT/US2021/033189 patent/WO2022031342A1/en not_active Ceased
- 2021-05-19 JP JP2023507951A patent/JP2023536746A/ja active Pending
- 2021-05-19 KR KR1020237007892A patent/KR20230080398A/ko active Pending
- 2021-05-19 CN CN202180068044.6A patent/CN117751132A/zh active Pending
- 2021-05-19 TW TW110118155A patent/TW202221022A/zh unknown
- 2021-05-19 AR ARP210101372A patent/AR122129A1/es unknown
- 2021-05-19 EP EP21854646.3A patent/EP4192583A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR122129A1 (es) | 2022-08-17 |
| EP4192583A4 (en) | 2025-02-12 |
| CA3188458A1 (en) | 2022-02-10 |
| KR20230080398A (ko) | 2023-06-07 |
| IL300346A (en) | 2023-04-01 |
| CN117751132A (zh) | 2024-03-22 |
| WO2022031342A1 (en) | 2022-02-10 |
| JP2023536746A (ja) | 2023-08-29 |
| US20230302127A1 (en) | 2023-09-28 |
| TW202221022A (zh) | 2022-06-01 |
| EP4192583A1 (en) | 2023-06-14 |
| AU2021321206A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001501A (es) | Vacuna tau para tratamiento de enfermedad de alzheimer. | |
| PH12022553234A1 (en) | Multi-epitope vaccine for the treatment of alzheimer`s disease | |
| MX2023003009A (es) | Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer. | |
| MX2023001503A (es) | Vacuna de multiples epitopos para tratamiento de la enfermedad de alzheimer. | |
| Magga et al. | Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease | |
| MX2023003008A (es) | Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer. | |
| KR102636129B1 (ko) | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 | |
| JP2017158561A5 (https=) | ||
| ATE535252T1 (de) | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit | |
| Gonsette et al. | Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing-remitting Multiple Sclerosis (ASIIMS) trial | |
| JPWO2019156137A5 (https=) | ||
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2023003007A (es) | Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias. | |
| US20250255939A1 (en) | Methods and compositions for inducing neural plasticity | |
| US20180344808A1 (en) | Haptoglobin derivative for treatment of sepsis and acetaminophen-induced liver damage | |
| JP2016539911A5 (https=) | ||
| Tucker et al. | Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide | |
| CN105612179B (zh) | 单克隆olfml-3抗体及其用途 | |
| JPWO2019093262A1 (ja) | 腸内環境制御による近視抑制 | |
| US10660935B2 (en) | Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide | |
| WO2016060190A1 (ja) | アミロイドβ蛋白質により誘発される認知障害の治療剤 | |
| AR122126A1 (es) | Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer | |
| US20210196799A1 (en) | Compositions for Use in the Treatment of Neurological Disease | |
| WO2023231402A1 (zh) | UbV.E4B蛋白的医药用途、药物组合物 | |
| Bailey | PTH-082 Dysregulated polyamines in the inflammatory bowel disease gut–a novel therapeutic target |